Resistance and refractoriness in obsessive-compulsive disorder (Q39325451)

11 September 2017

1 reference

title

Resistance and refractoriness in obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

11 September 2017

1 reference

Ygor Arzeno Ferrão

1

1 reference

11 September 2017

Juliana Belo Diniz

2

1 reference

11 September 2017

Antônio Carlos Lopes

3

1 reference

11 September 2017

Roseli Gedanke Shavitt

4

1 reference

11 September 2017

Benjamin Greenberg

5

1 reference

11 September 2017

Euripedes Miguel

6

1 reference

11 September 2017

language of work or name

non-English

0 references

publication date

1 October 2007

1 reference

Brazilian Journal of Psychiatry

11 September 2017

1 reference

11 September 2017

29 Suppl 2

1 reference

11 September 2017

S66-76

1 reference

Symptoms of obsessive-compulsive disorder

11 September 2017

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

The descriptive epidemiology of obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Adults with early-onset obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Obsessive-compulsive disorder phenotypes: implications for genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Clinical predictors of drug response in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Clinical features associated to refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Clinical features associated with treatment response in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Family accommodation in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Family approaches to treatment for obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Effects of perceived criticism on anxiety and depression during behavioral treatment of anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Quality of life in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Group versus individual cognitive-behavioural treatment for obsessive-compulsive disorder: a controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Outcome predictors for severe obsessive-compulsive patients in intensive residential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Open trial of cognitive behavior therapy for childhood obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

An update on the pharmacological treatment of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Enhanced Dopamine Transporter Density in Psychotropic-Naive Patients With Obsessive-Compulsive Disorder Shown by [ 123 I]β-CIT SPECT

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Neuroimaging and neurocircuitry models pertaining to the neurosurgical treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Hoarding and Treatment Response in 38 Nondepressed Subjects With Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

Effect of Axis II Diagnoses on Treatment Outcome With Clomipramine in 55 Patients With Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-44462006005000059

10.1590/S1516-44462006005000059

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference